| Sequencing Cohort | Replication Cohort | |||
---|---|---|---|---|---|
 |  | Control Subjects (n = 9) | RRMS Patients (n = 9) | Control Subjects (n = 18) | RRMS Patients (n = 20) |
Female | Â | 100% | 100% | 100% | 100% |
Caucasian | 100% | 90% | 94% | 100% | |
Age (years) | 34.75 (±11.45) | 42.44 (±9.66) | 38.92 (± 9.89) | 38.39 (±9.41) | |
Disease Duration (years) | N/A | 15.11 (±11.87) | N/A | 9.29 (±.5.52) | |
EDSS Score | 2.00 (±1.32) | 2.09 (±1.53) | |||
Age at Onset (years) | 27.94 (±8.48) | 28.96 (± 8.79) | |||
Number of Relapses | 5.98 (±4.91) | 6.35 (± 3.33) | |||
Days since Last Relapse | 1083.00 (±1271.81) | 985 (±969.75) | |||
Treatment | Off Treatment | 2 | 0 | ||
Dimethyl fumarate | 2 | 0 | |||
Fingolimod | 3 | 10 | |||
Natalizumab | 2 | 10 | |||
Time on Treatment (years) | 2.46 (±2.60) | 3.57 (±2.20) | |||
Number of Relapses on Treatment | 0.56 (±0.73) | 1.50 (±2.12) | |||
Most recent ARCSa | 78.33 (±26.76) | 81.35 (±20.43) |